Similar articles for PMID: 21816044

Year	Number of Results
1997	1
2001	1
2002	2
2003	2
2004	2
2005	3
2006	9
2007	6
2008	7
2009	14
2010	10
2011	6
2012	14
2013	10
2014	15
2015	8
2016	10
2017	5
2018	4
2019	2
2020	7
2021	10
2022	4
2024	0

1

Kinetic targeting of pegylated liposomal doxorubicin: a new approach to reduce toxicity during chemotherapy (CARL-trial).

Eckes J, Schmah O, Siebers JW, Groh U, Zschiedrich S, Rautenberg B, Hasenburg A, Jansen M, Hug MJ, Winkler K, Pütz G. Eckes J, et al. BMC Cancer. 2011 Aug 4;11:337. doi: 10.1186/1471-2407-11-337. BMC Cancer. 2011. PMID: 21816044 Free PMC article. Clinical Trial.

2

Plasmafiltration as a possible contributor to kinetic targeting of pegylated liposomal doxorubicin (PLD) in order to prevent organ toxicity and immunosuppression.

Martínková J, Bláha M, Kubeček O, Maláková J, Špaček J, Bezouška J, Krulichová IS, Filip S. Martínková J, et al. Cancer Chemother Pharmacol. 2016 Feb;77(2):429-37. doi: 10.1007/s00280-015-2936-z. Epub 2015 Dec 17. Cancer Chemother Pharmacol. 2016. PMID: 26678853

3

Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer.

Al-Batran SE, Meerpohl HG, von Minckwitz G, Atmaca A, Kleeberg U, Harbeck N, Lerbs W, Hecker D, Sehouli J, Knuth A, Jager E. Al-Batran SE, et al. Oncology. 2006;70(2):141-6. doi: 10.1159/000093005. Epub 2006 Apr 26. Oncology. 2006. PMID: 16645327 Clinical Trial.

4

Plasmafiltration as an effective method in the removal of circulating pegylated liposomal doxorubicin (PLD) and the reduction of mucocutaneous toxicity during the treatment of advanced platinum-resistant ovarian cancer.

Kubeček O, Martínková J, Chládek J, Bláha M, Maláková J, Hodek M, Špaček J, Filip S. Kubeček O, et al. Cancer Chemother Pharmacol. 2020 Feb;85(2):353-365. doi: 10.1007/s00280-019-03976-2. Epub 2019 Nov 14. Cancer Chemother Pharmacol. 2020. PMID: 31728628

5

Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.

Tanyi JL, Smith JA, Ramos L, Parker CL, Munsell MF, Wolf JK. Tanyi JL, et al. Gynecol Oncol. 2009 Aug;114(2):219-24. doi: 10.1016/j.ygyno.2009.04.007. Epub 2009 May 17. Gynecol Oncol. 2009. PMID: 19446868

6

Controlled application and removal of liposomal therapeutics: effective elimination of pegylated liposomal doxorubicin by double-filtration plasmapheresis in vitro.

Pütz G, Schmah O, Eckes J, Hug MJ, Winkler K. Pütz G, et al. J Clin Apher. 2010;25(2):54-62. doi: 10.1002/jca.20229. J Clin Apher. 2010. PMID: 20222030

7

Optimizing Antitumor Efficacy and Adverse Effects of Pegylated Liposomal Doxorubicin by Scheduled Plasmapheresis: Impact of Timing and Dosing.

Ngoune R, Contini C, Hoffmann MM, von Elverfeldt D, Winkler K, Putz G. Ngoune R, et al. Curr Drug Deliv. 2018;15(9):1261-1270. doi: 10.2174/1567201815666180518125839. Curr Drug Deliv. 2018. PMID: 29779479 Free PMC article.

8

Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.

Strauss HG, Hemsen A, Karbe I, Lautenschläger C, Persing M, Thomssen C. Strauss HG, et al. Anticancer Drugs. 2008 Jun;19(5):541-5. doi: 10.1097/CAD.0b013e3282fcbbf7. Anticancer Drugs. 2008. PMID: 18418221 Clinical Trial.

9

Plasma filtration for the controlled removal of liposomal therapeutics - From the apheretic site of view.

Blaha M, Martinkova J, Lanska M, Filip S, Malakova J, Kubecek O, Bezouska J, Spacek J. Blaha M, et al. Atheroscler Suppl. 2017 Nov;30:286-293. doi: 10.1016/j.atherosclerosissup.2017.05.022. Epub 2017 May 31. Atheroscler Suppl. 2017. PMID: 29096853

10

Extracorporeal Elimination of Circulating Pegylated Liposomal Doxorubicin (PLD) to Enhance the Benefit of Cytostatic Therapy in Platinum-Resistant Ovarian Cancer Patients.

Kubeček O, Bláha M, Diaz-Garcia D, Filip S. Kubeček O, et al. Acta Medica (Hradec Kralove). 2015;58(1):3-8. doi: 10.14712/18059694.2015.84. Acta Medica (Hradec Kralove). 2015. PMID: 26454800 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

135 results

Results by year